373110
Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. Xcell Therapeutics Inc. was incorporated in 2015 and is based in Seoul, South Korea.
373110 (373110) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: -0.481x
Based on the latest financial reports, 373110 (373110) has a cash flow conversion efficiency ratio of -0.481x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-5.45 Billion) by net assets (₩11.32 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
373110 - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how 373110's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
373110 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 373110 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Noram Lithium Corp
OTCQB:NRVTF
|
-0.046x |
|
Danel (Adir Yeoshua) Ltd
TA:DANE
|
0.035x |
|
Mangalam Global Enterprise Limited
NSE:MGEL
|
0.102x |
|
RLF Agtech Ltd
AU:RLF
|
-0.192x |
|
Mudajaya Group Bhd
KLSE:5085
|
-0.012x |
|
Leishen Energy Holding Co., Ltd. Ordinary Shares
NASDAQ:LSE
|
-0.034x |
|
Biofrontera Inc
NASDAQ:BFRI
|
1.481x |
|
The Good Flour Corp
PINK:GFCOF
|
0.061x |
Annual Cash Flow Conversion Efficiency for 373110 (2022–2024)
The table below shows the annual cash flow conversion efficiency of 373110 from 2022 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩9.12 Billion | ₩-7.00 Billion | -0.767x | +73.05% |
| 2023-12-31 | ₩2.38 Billion | ₩-6.78 Billion | -2.846x | -230.92% |
| 2022-12-31 | ₩8.48 Billion | ₩-7.30 Billion | -0.860x | -- |